Regarding prognostic outcomes, in the cohort of 18 AML patients harboring FLT3-ITD mutations, three individuals withdrew from treatment and were subsequently excluded from the prognostic evaluation. The gene discussed is FLT3; the disease is acute myeloid leukemia.